IPCA LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,339 INR | +0.82% |
|
+0.14% | +20.23% |
| 03-29 | Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director | CI |
| 03-29 | Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director | CI |
| Sales 2024 * | 75.75B 909M 1.24B | Sales 2025 * | 89.01B 1.07B 1.46B | Capitalization | 340B 4.07B 5.57B |
|---|---|---|---|---|---|
| Net income 2024 * | 6.32B 75.78M 104M | Net income 2025 * | 9.52B 114M 156M | EV / Sales 2024 * | 4.62 x |
| Net Debt 2024 * | 10.55B 127M 173M | Net Debt 2025 * | 4.59B 55.03M 75.24M | EV / Sales 2025 * | 3.87 x |
| P/E ratio 2024 * |
54.3
x | P/E ratio 2025 * |
35.6
x | Employees | 16,167 |
| Yield 2024 * |
0.35% | Yield 2025 * |
0.43% | Free-Float | 52.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ipca Laboratories Limited
More recommendations
| 1 day | +0.82% | ||
| 1 week | +0.14% | ||
| Current month | +8.10% | ||
| 1 month | +11.72% | ||
| 3 months | +20.11% | ||
| 6 months | +36.25% | ||
| Current year | +20.23% |
1 week
1 310.45
1 356.05
1 month
1 216.751 373.95
Current year
1 058.701 373.95
1 year
670.001 373.95
3 years
670.001 383.55
5 years
422.101 383.55
10 years
200.001 383.55
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 80-04-01 | |
Pranay Godha
CEO | Chief Executive Officer | 51 | 03-04-15 |
| Chairman | 77 | 75-10-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 77 | 75-10-30 | |
| Director/Board Member | 76 | 11-08-15 | |
Pranay Godha
CEO | Chief Executive Officer | 51 | 03-04-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1,339 | +0.82% | 4,551 |
| 24-04-25 | 1,328 | -1.47% | 8,879 |
| 24-04-24 | 1,347 | +1.80% | 10,817 |
| 24-04-23 | 1,324 | -0.40% | 10,560 |
| 24-04-22 | 1,329 | -0.58% | 3,749 |
Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am
More quotes
Ipca Laboratories Limited is an India-based pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIâs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
Sector
Pharmaceuticals
Calendar
2024-05-27
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
1,338
INR
Average target price
1,163
INR
Spread / Average Target
-13.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- IPCALAB Stock
- IPCALAB Stock
